The Myc proto-oncogene family consists of three members, C-MYC, MYCN, and MYCL,
which encodes the transcription factor c-Myc (hereafter Myc), N-Myc, and L-Myc …

Historically, cancers have been treated with chemotherapeutics aimed to have profound
effects on tumor cells with only limited effects on normal tissue. This approach was followed …

Systematic exploration of cancer cell vulnerabilities can inform the development of novel
cancer therapeutics. Here, through analysis of genome-scale loss-of-function datasets, we …

DNA repair genes are frequently mutated in cancer, yet limited data exist regarding the
overall genomic landscape and functional implications of these alterations in their entirety …

Synthetic lethality occurs when simultaneous perturbations of two genes or molecular
processes result in a loss of cell viability. The number of known synthetically lethal …

Introduction: Defects in the DNA damage response (DDR) drive the development of cancer
by fostering DNA mutation but also provide cancer-specific vulnerabilities that can be …

MYC is a transcription factor, which not only directly modulates multiple aspects of
transcription and co‐transcriptional processing (eg RNA‐Polymerase II initiation, elongation …

Deregulation of MYC is among the most frequent oncogenic drivers of cancer. Develo**
targeted therapies against MYC is, therefore, one of the most critical unmet needs of cancer …

Control theory is a well-established approach in network science, with applications in bio-
medicine and cancer research. We build on recent results for structural controllability of …

Synthetic lethality is a genetic phenomenon whereby the simultaneous presence of two
different genetic alterations impairs cellular viability. Importantly, targeting synthetic lethal …